0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.947437582128778
- age_years
- 58
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.461
- NOTCH_SIGNALING+0.424
- PROTEIN_SECRETION+0.408
- UNFOLDED_PROTEIN_RESPONSE+0.406
- INTERFERON_ALPHA_RESPONSE+0.368
- MYC_TARGETS_V2+0.343
- OXIDATIVE_PHOSPHORYLATION+0.317
- DNA_REPAIR+0.307
- MITOTIC_SPINDLE+0.296
- MTORC1_SIGNALING+0.295
Top 10 suppressed
- KRAS_SIGNALING_DN-0.395
- MYOGENESIS-0.276
- PANCREAS_BETA_CELLS-0.275
- SPERMATOGENESIS-0.220
- ANGIOGENESIS-0.195
- APICAL_JUNCTION-0.182
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.158
- ALLOGRAFT_REJECTION-0.154
- ESTROGEN_RESPONSE_LATE-0.141
- APICAL_SURFACE-0.115
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.930 |
| 2 | 10EE3CFC-9230-40BA-9C9F-77949BA763CC | — | — | 0.921 |
| 3 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.917 |
| 4 | SRR934762 | — | — | 0.906 |
| 5 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.904 |
| 6 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.900 |
| 7 | AFCB278F-0EFB-4999-8D2C-C72B89A8403E | — | — | 0.899 |
| 8 | 9B1A0E7C-F8DB-4FA0-9259-42A988D4E040 | — | — | 0.897 |
| 9 | 194676E1-632C-4B99-A9C8-80E36DD6C85E | — | — | 0.896 |
| 10 | E9D4A83F-EADA-4330-911A-8F02393E0BA3 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.461 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.424 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.408 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.406 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.368 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.343 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.317 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.307 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.296 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.295 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.293 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.282 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.273 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.272 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.263 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.253 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.203 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.199 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.163 | Inavolisib | — uncovered |